scispace - formally typeset
C

Chris J.L.M. Meijer

Researcher at VU University Amsterdam

Publications -  745
Citations -  83366

Chris J.L.M. Meijer is an academic researcher from VU University Amsterdam. The author has contributed to research in topics: Cervical cancer & Cervical intraepithelial neoplasia. The author has an hindex of 128, co-authored 733 publications receiving 78705 citations. Previous affiliations of Chris J.L.M. Meijer include VU University Medical Center & Academic Center for Dentistry Amsterdam.

Papers
More filters
Journal ArticleDOI

Persistent augmentation of natural-killer- and T-cell-mediated cytotoxicity in peripheral blood mononuclear cells pulsed in vitro with high-dose recombinant interleukin-2 prior to culturing with a low maintenance dose

TL;DR: In vitro studies of whether a single, peak rIL-2 dose, followed by low maintenance doses, could enhance the cytotoxic potential of peripheral blood mononuclear cells (PBMC) without inducing a significant sustained release of secondary cytokines, known to contribute to undesirable side-effects of therapy are described.
Journal ArticleDOI

Human papillomavirus prevalence in invasive cervical carcinoma by HIV Status

TL;DR: This study compares the prevalence of HPV types in ICC by HIV status to elucidate the influence of immunity on the carcinogenicity of different HPV types and the potential impact of prophylactic HPV vaccines in populations with high HIV prevalence.
Journal ArticleDOI

Immunohistochemical localization of pepsinogen A and C containing cells in Barrett's oesophagus.

TL;DR: It is concluded that pepsinogen-containing cells can be accurately identified in the Barrett's epithelium; their presence seems related to the histological cell type.
Journal ArticleDOI

Validation of ASCL1 and LHX8 Methylation Analysis as Primary Cervical Cancer Screening Strategy in South African Women with Human Immunodeficiency Virus

TL;DR: In this paper , the authors validated the accuracy of ASCL1/LHX8 methylation analysis for primary screening in WWH, which offers a full-molecular alternative to cytology- or HPV-based screening, without the need for additional triage testing.